SCHEMBL3092938

SCHEMBL3092938

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cc(F)ccc2OC)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
KAT6A Q92794 1/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
THRB P10828 1/20 0.43
HTT P42858 2/20 0.43
AHR P35869 2/20 0.41
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 2/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3099986 0.93 KAT6A (0.52) MEN1KMT2AALDH1A1MAPTKAT6A
SCHEMBL3096420 0.91 GPR27 (0.48) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL3093127 0.91 GPR27 (0.48) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL3097539 0.89 LARS1 (0.42) MEN1KMT2ALMNAMAPTKAT6A
SCHEMBL3088260 0.89 LARS1 (0.42) MEN1KMT2ALMNAMAPTKAT6A
SCHEMBL3088121 0.89 ALOX15 (0.43) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL3100518 0.88 NPC1 (0.51) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL3101165 0.88 NPC1 (0.51) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL3100331 0.88 LARS1 (0.39) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL3096442 0.88 LARS1 (0.42) MEN1KMT2ALMNAMAPTKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MEN1 2509/4885KMT2A 1948/4885KDM4E 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.